Literature DB >> 10404322

Comparative in-vitro activity of moxifloxacin, minocycline and azithromycin against Chlamydia spp.

M Donati1, M Rodrìguez Fermepin, A Olmo, L D'Apote, R Cevenini.   

Abstract

The in-vitro activity of moxifloxacin, a new 8-methoxyquinolone, was compared with minocycline and azithromycin against 40 strains of Chlamydia trachomatis, Chlamydia pneumoniae and Chlamydia psittaci. Both the MIC and the MBC of moxifloxacin ranged from 0.03 to 0.125 mg/L. MICs of minocycline ranged from 0.015 to 0.06 mg/L and MBCs between 0.03 and 0.25 mg/L. MICs of azithromycin ranged from 0.03 to 0.125 mg/L and the MBCs between 0.06 and 0.5 mg/L. MBC values of moxifloxacin were the same as MICs in 32 (80%) of 40 strains tested, whereas those of minocycline and azithromycin were two to four times higher than their MICs. These data confirm those previously obtained indicating that quinolones kill chlamydial strains at concentrations equivalent to their MICs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10404322     DOI: 10.1093/jac/43.6.825

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  21 in total

1.  In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K.

Authors:  Manuela Donati; Antonietta Di Francesco; Antonietta D'Antuono; Federica Delucca; Alisa Shurdhi; Alessandra Moroni; Raffaella Baldelli; Roberto Cevenini
Journal:  Antimicrob Agents Chemother       Date:  2010-09-20       Impact factor: 5.191

2.  Distinctive features between community-acquired pneumonia (CAP) due to Chlamydophila psittaci and CAP due to Legionella pneumophila admitted to the intensive care unit (ICU).

Authors:  A Gacouin; M Revest; J Letheulle; P Fillatre; S Jouneau; C Piau; F Uhel; P Tattevin; Y Le Tulzo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-04-28       Impact factor: 3.267

3.  Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial.

Authors:  J D C Ross; H S Cronjé; T Paszkowski; I Rakoczi; D Vildaite; A Kureishi; M Alefelder; P Arvis; P Reimnitz
Journal:  Sex Transm Infect       Date:  2006-05-24       Impact factor: 3.519

4.  Application of DNA chip scanning technology for automatic detection of Chlamydia trachomatis and Chlamydia pneumoniae inclusions.

Authors:  Anita Bogdanov; Valeria Endrész; Szabolcs Urbán; Ildikó Lantos; Judit Deák; Katalin Burián; Kamil Önder; Ferhan Ayaydin; Péter Balázs; Dezso P Virok
Journal:  Antimicrob Agents Chemother       Date:  2013-11-04       Impact factor: 5.191

5.  Application of metagenomic next-generation sequencing (mNGS) combined with rapid on-site cytological evaluation (ROSCE) for the diagnosis of Chlamydia psittaci pneumonia.

Authors:  Qian Zhang; Shuo Li; Wei Zhou; Liwen Zheng; Yi Ren; Lixia Dong; Jing Feng; Jie Cao
Journal:  Int J Clin Exp Pathol       Date:  2021-04-15

Review 6.  Acute exacerbations of chronic bronchitis: what role for the new fluoroquinolones?

Authors:  A Obaji; S Sethi
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 7.  A critical review of the fluoroquinolones: focus on respiratory infections.

Authors:  George G Zhanel; Kelly Ennis; Lavern Vercaigne; Andrew Walkty; Alfred S Gin; John Embil; Heather Smith; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 8.  Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections.

Authors:  J A Balfour; H M Lamb
Journal:  Drugs       Date:  2000-01       Impact factor: 9.546

9.  Mycoplasma genitalium: should we treat and how?

Authors:  Lisa E Manhart; Jennifer M Broad; Matthew R Golden
Journal:  Clin Infect Dis       Date:  2011-12       Impact factor: 9.079

10.  Methodologies and cell lines used for antimicrobial susceptibility testing of Chlamydia spp.

Authors:  R J Suchland; W M Geisler; Walter E Stamm
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.